Repository logo
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • Research Outputs
  • Projects
  • People
  • Statistics
  • English
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Log In
    or
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Scholalry Output
  3. Publications
  4. A short review on important drugs under clinical trial against covid-19
 
  • Details
Options

A short review on important drugs under clinical trial against covid-19

ISSN
13895575
Date Issued
2021-08-01
Author(s)
Misra, Namita
DOI
10.2174/1389557521666201217145333
Abstract
Coronavirus spreads from one to another person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. COVID-19 infected human symptoms are like pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. It was first notified in China dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures, everyone should follow the World Health Organization's advice guidelines on the management of humans infected with known or suspected infection with the SARS-CoV-2 virus at the personal level. The development of vaccine or medicines for the same is in progress and this short review will summarize the most potential candidates such as Remdesivir, Lopinavir and Ritonavir, Chloroquine, Hydroxychloroquine, Hydroxychloroquine with Azithromycin, Favipiravir, Umifenovir, and Ribavirin for its medicinal treatment.
Subjects
  • COVID-19

  • Pneumonia

  • SARS-CoV-2

  • URI

  • WHO

Copyright © 2016-2025  Indian Institute of Technology Jodhpur

Developed and maintained by Dr. Kamlesh Patel and Team, S. R. Ranganathan Learning Hub, IIT Jodhpur.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback